NEW YORK — Sager’s pharmaceuticals is “stunningly high,” according to a recent report by Bloomberg.
The biotech company reported a profit of $1.2 billion for the year ended March 31, and analysts said the company had $8 billion in cash.
The company’s stock has jumped $1,871 per share since Bloomberg’s report.
The stock price is up nearly 60% from its $2.00 level in the first quarter.
It has risen over 20% this year and has more than doubled since the start of 2018.